Homepage
Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.

Damora Therapeutics develops targeted biologic therapies for blood disorders.
damoratx.comCrawled Oct 16, 2026
Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
Damora Therapeutics has a privacy policy.
Damora Therapeutics reports strong financial performance and progress in its lead asset, **DMR-001**, targeting mid-2026 for an Investigational New Drug (IND) or Clinical Trial Application (CTA) submission. The company anticipates two clinical proof-of-concept datasets by mid-2027, marking key milestones in its development pipeline. Recent corporate updates highlight operational advancements and strategic initiatives to support clinical and regulatory timelines.
Damora Therapeutics, formerly Galecto, rebrands after acquiring privately held Damora and securing a $285 million private investment. The biotech company focuses on transforming care for patients with blood disorders through its expanded platform. The name change reflects the integration of Damora’s assets and the company’s renewed strategic direction.
Galecto acquires Damora Tx to expand its therapeutic pipeline. The company secures **US$285 million** in Series C funding, led by new investors. Damora Tx’s technology targets immune-related diseases, complementing Galecto’s focus on galectin inhibitors.
Galecto, Inc. acquires Damora Therapeutics and secures $284 million in an oversubscribed private placement. The company’s shares rise 214% to $15.56 following the announcement. The funding and acquisition expand Galecto’s focus on therapeutic development.
Galecto, Inc. acquires Damora Therapeutics, Inc. in a deal announced on November 10, 2025. The transaction consolidates biotech assets, with Lucid Capital Markets advising on financial structuring and Mintz Levin serving as legal counsel. Both firms specialize in life sciences and corporate transactions.